Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Jaguar Health, Inc. - Common Stock (NQ:JAGX)

0.9160 +0.1329 (+16.97%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,222,870
Open 0.7700
Bid (Size) 0.9181 (300)
Ask (Size) 0.9200 (600)
Prev. Close 0.7831
Today's Range 0.7407 - 1.000
52wk Range 0.7250 - 91.00
Shares Outstanding 171,350,166
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Jaguar Health Satisfies Conditions for Receipt of Non-Dilutive $2 Million Holdback Payment from Future Pak for Commercial License to Mytesi and Canalevia-CA1
From Jaguar Health, Inc.
Via ACCESS Newswire
News headline image
Jaguar Health Reports Positive Consumer and Veterinary Market Research Findings Supporting Commercial Opportunity for Neonorm Dog
From Jaguar Health, Inc.
Via ACCESS Newswire

Performance

YTD
-97.4%
-97.4%
1 Month
-57.8%
-57.8%
3 Month
-76.8%
-76.8%
6 Month
-95.5%
-95.5%
1 Year
-99.0%
-99.0%

More News

Read More
News headline image
Additional Infant Patient to Receive Jaguar Health's Crofelemer for Compassionate Use for Treatment of Intestinal Failure (IF) Due to Microvillus Inclusion Disease (MVID)
From Jaguar Health, Inc.
Via ACCESS Newswire
What's going on in today's session ↗
Via Chartmill
News headline image
Jaguar Health Compliant with Nasdaq Bid Price Rule
Via ACCESS Newswire
Jaguar Health Inc (NASDAQ:JAGX) Swings to Profit on Licensing Deal, But Market Sells the News ↗
Via Chartmill
News headline image
Presentation at ESPGHAN 2026 Describes Additional Groundbreaking Results of Evaluation of Jaguar Health's Crofelemer as Adjunctive Oral Therapy for the Treatment of Pediatric Intestinal Failure (IF)
From Jaguar Health, Inc.
Via ACCESS Newswire
News headline image
Life Sciences Virtual Investor Forum Presentations Now Available for On-Demand Viewing
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
Jaguar Health Announces Conversion of Series O Convertible Preferred Stock Issued as Recent One-time Stock Dividend
From Jaguar Health, Inc.
Via ACCESS Newswire
News headline image
Jaguar Health Completes Submission of New Animal Drug Application for Full FDA Approval of Crofelemer for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs
From Jaguar Health, Inc.
Via ACCESS Newswire
News headline image
Life Sciences Virtual Investor Forum Agenda Announced for June 24th & 25th
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
Jaguar Health Announces Plan to Explore Strategic Alternatives Aligned with Targeted NDA Filing for Rare Disease Intestinal Failure Program
From Jaguar Health, Inc.
Via ACCESS Newswire
News headline image
Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, Announces Positive Results of Preclinical Study of Coca for Weight Gain Prevention
From Jaguar Health, Inc.
Via ACCESS Newswire
News headline image
Jaguar Health Presenting June 24, 2026 at the Life Sciences Virtual Investor Forum to Provide Updates on Company's Crofelemer Development Program for Rare Intestinal Failure Diseases
Via ACCESS Newswire
News headline image
Jaguar Health Reports Approval of All Proposals at 2026 Annual Meeting of Stockholders
Via ACCESS Newswire
News headline image
Jaguar Health Research in Ethnobotanical Medicine Helps Advance Crofelemer Development for Genetically Defined Rare Congenital Gastrointestinal Disorders
Via ACCESS Newswire
News headline image
Jaguar Health (JAGX) Q3 2025 Earnings Transcript ↗
Via The Motley Fool
Wondering what's happening in today's after-hours session? ↗
Via Chartmill
News headline image
Jaguar Health Reports First Quarter 2026 Financials
Via ACCESS Newswire
News headline image
Jaguar (JAGX) Q4 2025 Earnings Transcript ↗
Via The Motley Fool
News headline image
Jaguar Health Announces Active Treatment Only Continuation of Pivotal Multicenter Clinical Trial in Pediatric Patients with Microvillus Inclusion Disease (MVID) to Support a New Drug Application (NDA) for Liquid Oral Crofelemer
Via ACCESS Newswire
News headline image
Jaguar Health Regains Compliance with Nasdaq's Publicly Held Shares Requirement and Receives Additional Extension, Until May 18, 2026, to Demonstrate Compliance with Nasdaq's Bid Price Rule
Via ACCESS Newswire
News headline image
Jaguar Health Announces Preliminary Discussion with FDA to Evaluate Breakthrough Therapy Designation for Crofelemer for Treatment of Microvillus Inclusion Disease (MVID)
Via ACCESS Newswire
These stocks are moving in today's session ↗
Via Chartmill
Let's have a look at the top gainers and losers in the middle of the day of today's session. ↗
Via Chartmill

Frequently Asked Questions

Is Jaguar Health, Inc. - Common Stock publicly traded?
Yes, Jaguar Health, Inc. - Common Stock is publicly traded.
What exchange does Jaguar Health, Inc. - Common Stock trade on?
Jaguar Health, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Jaguar Health, Inc. - Common Stock?
The ticker symbol for Jaguar Health, Inc. - Common Stock is JAGX on the Nasdaq Stock Market
What is the current price of Jaguar Health, Inc. - Common Stock?
The current price of Jaguar Health, Inc. - Common Stock is 0.9160
When was Jaguar Health, Inc. - Common Stock last traded?
The last trade of Jaguar Health, Inc. - Common Stock was at 08/14/26 04:00 PM ET
What is the market capitalization of Jaguar Health, Inc. - Common Stock?
The market capitalization of Jaguar Health, Inc. - Common Stock is 156.96M
How many shares of Jaguar Health, Inc. - Common Stock are outstanding?
Jaguar Health, Inc. - Common Stock has 157M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.